低剂量阿司匹林作为全关节置换术后临床重要静脉血栓栓塞症的有效化学预防:初步分析
前瞻性交叉研究纳入2013年7月至2015年6月4651例初次全关节置换术病例,3192例接受325毫克阿司匹林每日两次,1459例接受81毫克阿司匹林每日两次,持续4周。低剂量组静脉血栓栓塞症发生率为0.1%,高剂量组为0.3%,两组差异无统计学意义(p=0.345);低剂量组胃肠道出血或溃疡发生率略低但无显著差异(p=0.66)。结论认为低剂量阿司匹林在静脉血栓栓塞症预防方面不劣于高剂量阿司匹林。
要点
- 81毫克阿司匹林组静脉血栓栓塞症发生率为0.1%(95%CI 0%至0.3%),325毫克组为0.3%(95%CI 0.1%至0.6%),p=0.345。
- 81毫克组胃肠道出血或溃疡发生率为0.3%(95%CI 0%至0.5%),略低于325毫克组的0.4%(95%CI 0.2%至0.6%),p=0.66。
- 81毫克组急性假体周围关节感染发生率为0.2%(95%CI 0%至0.4%),325毫克组为0.5%(95%CI 0.2%至0.7%),p=0.28。
核心结论
- 本研究表明,低剂量阿司匹林在全关节置换术后静脉血栓栓塞症预防方面不劣于高剂量阿司匹林。
- 作者指出这一结果并不意外,因为现有文献显示低剂量阿司匹林在预防急性冠脉综合征和脑血管事件方面与较高剂量阿司匹林同样有效。
研究设计与样本
- 前瞻性交叉研究,分析2013年7月至2015年6月实施的4651例初次全关节置换术病例。
- 3192例患者接受肠溶阿司匹林325毫克每日两次治疗4周(325毫克阿司匹林组),1459例患者接受阿司匹林81毫克每日两次治疗4周(81毫克阿司匹林组)。
- 两组患者在性别、体重指数或查尔森合并症指数方面无显著差异(p>0.05)。
- 记录术后90天内发生的并发症,包括症状性静脉血栓栓塞症(深静脉血栓形成和肺栓塞)、胃肠道并发症、急性假体周围关节感染和死亡。
- 证据等级:治疗性II级。
主要发现
- 81毫克阿司匹林组静脉血栓栓塞症发生率为0.1%(95%CI 0%至0.3%,1例深静脉血栓形成和1例肺栓塞),325毫克阿司匹林组为0.3%(95%CI 0.1%至0.6%,7例深静脉血栓形成和5例肺栓塞),两组差异无统计学意义(p=0.345)。
- 81毫克阿司匹林组胃肠道出血或溃疡发生率为0.3%(95%CI 0%至0.5%),略低于325毫克阿司匹林组的0.4%(95%CI 0.2%至0.6%),但差异无统计学意义(p=0.66)。
- 81毫克阿司匹林组急性假体周围关节感染发生率为0.2%(95%CI 0%至0.4%),325毫克阿司匹林组为0.5%(95%CI 0.2%至0.7%),p=0.28。
- 81毫克阿司匹林组90天死亡率为0.1%(95%CI 0%至0.2%),325毫克阿司匹林组为0.1%(95%CI 0%至0.2%),两组相似(p=0.78)。
关键数值与推荐
- 81毫克阿司匹林组静脉血栓栓塞症发生率0.1%(95%CI 0%至0.3%)vs 325毫克阿司匹林组0.3%(95%CI 0.1%至0.6%),p=0.345,差异无统计学意义。
- 81毫克阿司匹林组胃肠道出血或溃疡发生率0.3%(95%CI 0%至0.5%)vs 325毫克阿司匹林组0.4%(95%CI 0.2%至0.6%),p=0.66,差异无统计学意义。
- 81毫克阿司匹林组急性假体周围关节感染发生率0.2%(95%CI 0%至0.4%)vs 325毫克阿司匹林组0.5%(95%CI 0.2%至0.7%),p=0.28。
- 81毫克阿司匹林组90天死亡率0.1%(95%CI 0%至0.2%)vs 325毫克阿司匹林组0.1%(95%CI 0%至0.2%),p=0.78,两组相似。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Aspirin is a safe and effective prophylaxis for the prevention of venous thromboembolism following total joint arthroplasty. The optimal dose of aspirin prophylaxis is unknown. Our hypothesis was that lower-dose aspirin is as effective as higher-dose aspirin for the prevention of venous thromboembolism and is associated with fewer gastrointestinal side effects. METHODS: In a prospective, crossover study, we analyzed 4,651 primary total joint arthroplasty cases performed from July 2013 to June 2015. For 4 weeks, 3,192 patients received enteric-coated 325-mg aspirin twice daily (the 325-mg aspirin group) and 1,459 patients received 81-mg aspirin twice daily (the 81-mg aspirin group). There were no significant differences (p > 0.05) in sex, body mass index, or Charlson Comorbidity Index between the two patient populations. Recorded complications occurring within 90 days postoperatively included symptomatic venous thromboembolism (deep venous thrombosis and pulmonary embolism), gastrointestinal complications, acute periprosthetic joint infection, and death. RESULTS: The incidence of venous thromboembolism of 0.1% (95% confidence interval [CI], 0% to 0.3%) in the 81-mg aspirin group (1 with deep venous thrombosis and 1 with pulmonary embolism) was not significantly different (p = 0.345) from 0.3% (95% CI, 0.1% to 0.6%) in the 325-mg aspirin group (7 with deep venous thrombosis and 5 with pulmonary embolism). The incidence of gastrointestinal bleeding or ulceration of 0.3% (95% CI, 0% to 0.5%) in the 81-mg aspirin group was slightly, but not significantly (p = 0.66), lower than the 0.4% (95% CI, 0.2% to 0.6%) in the 325-mg aspirin group. The incidence of acute periprosthetic joint infection was 0.2% (95% CI, 0% to 0.4%) in the 81-mg aspirin group compared with 0.5% (95% CI, 0.2% to 0.7%) in the 325-mg aspirin group (p = 0.28). The 90-day mortality rate was similar in both groups at 0.1% (95% CI, 0% to 0.2%) in the 81-mg aspirin group and 0.1% (95% CI, 0% to 0.2%) in the 325-mg aspirin group (p = 0.78). CONCLUSIONS: Our study demonstrates that low-dose aspirin is not inferior to high-dose aspirin for venous thromboembolism prophylaxis following total joint arthroplasty. This is not unexpected, as the available literature demonstrates that low-dose aspirin is as effective as higher-dose aspirin in the prevention of acute coronary syndrome and cerebrovascular events. LEVEL OF EVIDENCE: Therapeutic Level II. See Instructions for Authors for a complete description of levels of evidence.
引用
- Parvizi J, Huang R, Restrepo C, et al. Low-Dose Aspirin Is Effective Chemoprophylaxis Against Clinically Important Venous Thromboembolism Following Total Joint Arthroplasty: A Preliminary Analysis. J Bone Joint Surg Am. 2017. PMID: 28099298. doi:10.2106/JBJS.16.00147
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。